MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

MAIA Biotechnology (MAIA) announced that the United States Adopted Names Council has approved “ateganosine” as the nonproprietary name for its ...

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO ...

Novel THIO dimer shows promise as a new compound with a dual mechanism of action for enhancing standard cancer treatments and overcoming resistance MAIA Biotechnology, Inc., (NYSE American ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment ...

(RTTNews) - MAIA Biotechnology Inc. (MAIA), on Wednesday ... nonproprietary name for its investigational anticancer agent, THIO. The approval is an important step in the regulatory process ...

MAIA Biotechnology, Inc. has reported significant advancements in its clinical-stage developments. The company announced promising results from its Phase 2 THIO-101 trial, showing a median overall ...